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Edited by Masayuki MiyasakaAbstract CRTH2 is a recently described chemoattractant
receptor for the prostaglandin, PGD2, expressed by Th2 cells,
eosinophils and basophils, and believed to play a role in allergic
inﬂammation. Here we describe the potency of several PGD2
metabolites at the receptor to induce cell migration and activa-
tion. We report for the ﬁrst time that the PGD2 metabolite,
9a,11b-PGF2, and its stereoisomer, PGF2a, are CRTH2 ago-
nists. 9a,11b-PGF2 is a major metabolite produced in vivo fol-
lowing allergen challenge, whilst PGF2a is generated
independently of PGD synthetase, with implications for CRTH2
signalling in the presence or absence of PGD2 production.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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PGD2 is the major prostaglandin (PG) released by mast cells
following activation [1], and mice over-expressing PGD syn-
thase exhibit marked eosinophil and T-lymphocyte recruit-
ment to the lung [2], implying a role for the PG in allergic
inﬂammation. PGD2 signals through the DP receptor [3],
and in a model of allergic airway inﬂammation, mice lacking
DP failed to develop airway hyperreactivity and showed re-
duced cell inﬁltration [4]. Recently, a novel PGD2 receptor,
chemoattractant receptor homologous molecule expressed by
Th2 cells (CRTH2), was identiﬁed [5], which is expressed by
eosinophils, Th2 cells and basophils [6] and facilitates the
migration of these cells in response to PGD2 [5].
PGD2 is a labile molecule [7,8], and the PGD2 metabolites,
D12-PGD2, 15d-PGD2, 15d-PGJ2, D
12-PGJ2 and PGJ2 (de-
picted in Fig. 1), have been shown to bind to CRTH2
[5,9,10] and to activate eosinophils [10–12]. 9a,11b-PGF2 is
generated from PGD2 by the action of PGF synthase [13]Abbreviations: CRTH2, chemoattractant receptor homologous mole-
cule expressed by Th2 cells; GAFS, gated auto-ﬂuorescence forward
scatter assay; PG, prostaglandin; PGDS, PGD2 synthetase
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doi:10.1016/j.febslet.2005.11.052and is one of the major metabolites of PGD2 formed in vivo
[13,14], being found in the urine and plasma of asthmatics fol-
lowing allergen challenge [15,16]. PGF2a is a stereoisomer of
9a,11b-PGF2 (Fig. 1), produced from PGH2 by the action of
PGF synthase [17], and from PGE2 by the action of PGE 9-
ketoreductase [18]. PGF2a, 9a,11b-PGF2 and PGD2 have been
reported to cause smooth muscle contraction with similar po-
tency [19], and the three PGs exhibit potent bronchoconstric-
tor activity [20]. 9a,11b-PGF2 and PGF2a exhibit activity at
DP, albeit with lower aﬃnity than PGD2 [19,21]. In addition,
9a,11b-PGF2 has been demonstrated to induce the upregula-
tion of CD11b on eosinophils [11], and to inhibit cAMP gen-
eration in CRTH2 transfected cells [9], whilst PGF2a induced
actin polymerisation and CD11b upregulation in eosinophils
[22], and in CRTH2 transfectants, induced calcium mobilisa-
tion and inhibited cAMP generation, actions presumably med-
iated by CRTH2. Here we provide further evidence that
9a,11b-PGF2 and PGF2a are CRTH2 agonists, and character-
ise their eﬀects at this receptor.2. Materials and methods
2.1. Materials
Unless otherwise stated, all reagents were from Sigma–Aldrich
(Poole, UK). PGs and ramatroban were from Cayman Chemicals
(MI, USA), and tissue culture reagents were from Invitrogen (Paisley,
UK).
2.2. Cell culture
Naı¨ve BaF/3 cells and those stably expressing CRTH2
(CRTH2.BaF/3 cells) were cultured as described [23].
2.3. Chemotaxis assay
Assays were carried out as previously described [23]. Brieﬂy, agonists
were diluted in RPMI + 0.1% BSA and placed in the wells of a 96 well
Neuroprobe chemotaxis plate (Receptor Technologies, UK). 2 · 105
cells were placed on top of the ﬁlter and the plate incubated at
37 C, 5% CO2, in a humidiﬁed box for 5 h. Cells traversing the ﬁlter
were counted on a haemocytometer. Results are expressed as the per-
centage of migrating cells, following the subtraction of basal migra-
tion, to buﬀer alone.
2.4. Preparation of granulocytes
Granulocytes were prepared as described [24]. Peripheral venous
blood from healthy volunteers was anticoagulated with trisodium cit-
rate. Platelets were removed by centrifugation, and erythrocytes by
dextran sedimentation. Leukocytes were separated according toblished by Elsevier B.V. All rights reserved.
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Fig. 1. The structures of the PGD2 metabolites of interest, modiﬁed from [8], PGF2a, PGE2 and PGA2.
374 H. Sandig et al. / FEBS Letters 580 (2006) 373–379density by centrifugation over Histopaque 1077. Residual erythrocytes
were removed by hypotonic lysis. Granulocytes were resuspended in
handling buﬀer (0.1% BSA, 10 mM glucose, 10 mM HEPES in PBS
without Ca2+ and Mg2+, pH 7.4).
2.5. Eosinophil gated-autoﬂuorescence forward scatter assay (GAFS)
The GAFS assay was performed as described [25]. Granulocytes
were incubated at room temperature for 1 h in handling buﬀer and
resuspended in GAFS assay buﬀer (handling buﬀer with Ca2+ and
Mg2+). 5 · 105 cells were added to the indicated agonist, incubated
for 4 min at 37 C, and the cells ﬁxed by the addition of 1· CellFix
(Becton-Dickinson, Cowley, UK) which had been further diluted 1:4
with FACSFlow sheath ﬂuid. Data were aquired on a FACSCalibur
ﬂow cytometer, with collection terminated once 500 high FL-2 events
(eosinophils) had been acquired [25]. Agonist induced eosinophil shape
change was calculated as a percentage of the baseline forward scatter
(FSC).
2.6. Statistical analysis
Statistical analyses, curve ﬁtting, and calculation of EC50 values was
performed using Prism 3.0 (Graphpad Software Inc., San Diego,
USA).3. Results
3.1. Relative activities of PGD2 metabolites at CRTH2
PGD2, PGJ2, D
12-PGJ2, 15d-PGJ2, DK-PGD2, D
12-PGD2
and 15d-PGD2 induced the migration of BaF/3 cells stablyexpressing CRTH2 (Fig. 2) but had no eﬀect on the migration
of naı¨ve cells (data not shown), implying that this response is
mediated by CRTH2. Although two orders of magnitude less
potent than PGD2, the J-series PGs were the most eﬃcacious
agonists tested at inducing chemotaxis of these cells
(Fig. 2,A–D).
As previously reported [23], PGD2 induced a potent shape
change response in eosinophils with activity in the sub-nano-
molar range. The PGD2 metabolites also induced eosinophil
shape change (Fig. 3), with a rank order of potency of
PGD2 = 15d-PGD2 > D
12-PGD2 = DK-PGD2 > PGJ2 > D
12-
PGJ2 = 15d-PGJ2. Calculated EC50 values for these re-
sponses are shown in Table 1. The responses appeared to
be mediated via CRTH2 rather than DP as they were com-
pletely abrogated by pretreatment of the leukocytes with the
CRTH2 antagonist, ramatroban (Table 1), which had no ef-
fect on the CCR3-mediated response to eotaxin (data not
shown).
3.2. 9a,11b-PGF2 and PGF2a cause eosinophil activation
Both 9a,11b-PGF2 and PGF2a showed similar eﬃcacy to
PGD2 in assays of eosinophil shape change, but were less
potent than PGD2 (P < 0.0001) with EC50 values of
1.56 · 107 and 1.47 · 107 M, respectively (Fig. 4A and
B). Ramatroban inhibited these responses in a dose depen-
dent manner (Fig. 4C and D), suggesting that they were
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Fig. 2. The migratory response of CRTH2.BaF/3 cells in response to PGD2 and some of its metabolites is shown. Results are the means ± S.E.M. of
n = 4–8 experiments. \ indicates P < 0.05, \\, P < 0.01, and \\\, P < 0.001, by ANOVA with Friedman post test, comparing the number of cells
migrating to PG with the number migrating to buﬀer alone.
Table 1
The EC50 values of PG-induced eosinophil shape change were calculated and are given with the 95% conﬁdence intervals (n = 5–8)
EC50(M) 95% CI for EC 50(M) IC50for ramatroban (M)
PGD2 3.94 · 1010 1.95 · 1010–7.98 · 1010 2.73 · 109 (1 nM)
DK-PGD2 1.13 · 109* 5.26 · 1010–2.45 · 109 1.06 · 108 (10 nM)
PGJ2 2.22 · 109** 8.99 · 1010–5.49 · 109 1.04 · 108(10 nM)
D12-PGJ2 3.74 · 109*** 2.43 · 109–5.75 · 109 3.40 · 109 (10 nM)
15d-PGJ2 8.37 · 109*** 3.97 · 109–1.76 · 108 1.97 · 108(100 nM)
D12-PGD2 7.34 · 1010* 2.86 · 1010–1.88 · 109 4.40 · 109(3 nM)
15d-PGD2 2.39 · 1010 8.98 · 1011–6.35 · 1010 6.15 · 108(10 nM)
EC50 values of the tested PG were compared to that of PGD2 by t test.
* indicates P < 0.05, **, P < 0.005, and ***, P < 0.0001. IC50 values for the
inhibition of the response by a 10 min pretreatment with ramatroban are also given, with the PG concentrations used to generate a response indicated
in parenthesis (n = 4).
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Fig. 3. Panels A–G show eosinophil shape change in response to a range of concentrations of PG. Results are the means ± S.E.M. of n = 5–8
experiments.
376 H. Sandig et al. / FEBS Letters 580 (2006) 373–379mediated via CRTH2. Ramatroban is also an antagonist of
the TP receptor, but it seems unlikely that these responses
are due to TP signalling as there is no evidence for TP on
eosinophils [22].3.3. 9a,11b-PGF2 and PGF2a, but not PGA2 or PGE2, are
agonists of CRTH2
9a,11b-PGF2 and PGF2a induced migration of the CRTH2
transfectants, with 100-fold less potency than PGD2 (Fig. 5A
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Fig. 4. Panels A and B show the eosinophil shape change induced by 9a,11b-PGF2, PGF2a and PGD2. Panels C and D show eosinophil shape change
to 1 lM 11b-PGF2a or PGF2a, respectively, in the presence of the indicated ramatroban concentrations. Results are the means ± S.E.M. of n = 4
experiments.
Fig. 5. Panels B and D, naı¨ve Baf/3 cells, and A, C and E, CRTH2 expressing BaF/3 cells, were exposed to the indicated concentrations of PG for
5 h, and the resulting migration determined. Results are means ± S.E.M. of n = 3 (B, D and E) or n = 5 (A and C) experiments. \ indicates P < 0.05
and \\, P < 0.01 by ANOVA with Friedman post test comparing the number of cells migrating to PG to the number migrating to buﬀer.
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378 H. Sandig et al. / FEBS Letters 580 (2006) 373–379and C). Naı¨ve BaF/3 cells were unresponsive to both PGs, de-
spite migrating to the chemokine SDF-1a via endogenous
CXCR4 (Fig. 5B and D), implying that the migratory response
is mediated via the presence of CRTH2.
As CRTH2 is activated by PGs containing D, J and F rings,
it was of interest to establish whether PGs with the A or E ring
could also activate the receptor. Neither PGA2 nor PGE2
(structures shown in Fig. 1) caused the migration of BaF/3 cells
expressing CRTH2, at a range of concentrations active for the
other CRTH2 agonists (Fig. 5,E and F).4. Discussion
CRTH2 is a remarkably promiscuous receptor, with ligands
including PGD2 and its metabolites, a TXA2 metabolite and
the non-steroidal anti-inﬂammatory drug indomethacin
[5,10–12,23,24,26]. PGF2a and 9a,11b-PGF2a have been previ-
ously demonstrated to stimulate CRTH2 transfectants [9] and
eosinophils [11,22]. Here, we investigate the ability of the pros-
taglandins to induce the migration of CRTH2 transfected cells,
and with the use of an antagonist, demonstrate for the ﬁrst
time that 9a,11b-PGF2 PGF2a, and several PGD2 metabolites
stimulate eosinophils via CRTH2.
The J-series PGs caused eosinophil shape change and the
migration of CRTH2 transfected BaF/3 cells with less po-
tency than PGD2 itself, reﬂecting the ﬁndings of previous
studies [5,9,11]. Studies have shown that high concentrations
of 9a,11b-PGF2 and PGF2a are able to displace radiola-
belled PGD2 from CRTH2 [5,9], in agreement with our
ﬁndings that these PGs signal via CRTH2, although with
lower potency than PGD2. PGs containing the A or E ring
were inactive at CRTH2, suggesting CRTH2 is not activated
by PGs containing a ketone at carbon 9. In contrast, the
identity of the group at carbon 11 appears to be less impor-
tant, as the F-series PGs with a hydroxyl at this position
rather than the ketone of PGD2 are able to activate the
receptor.
Whilst 9a,11b-PGF2a is several orders of magnitude less po-
tent than PGD2, it is reported to be more stable in vivo, as fol-
lowing administration of PGD2 to humans, 9a,11b-PGF2 but
not PGD2 was found in the urine [14]. It is therefore likely that
the metabolite may accumulate in vivo. Indeed, plasma levels
of 1.4 lM have been reported in a patent with severe mastocy-
tosis [27], whilst a mean concentration of 42.3 pM was found
in the plasma of allergen challenged asthmatics [15]. It there-
fore seems plausible that levels of 9a,11b-PGF2a at concentra-
tions suﬃcient to activate CRTH2 are generated in vivo. Since
PGD2 is produced in the lung in response to allergen challenge
[28], and PGF synthase is also expressed in the lung [29,30], lo-
cal generation of 9a,11b-PGF2amay play a role in allergic lung
inﬂammation by activating eosinophils, Th2 cells and baso-
phils, via CRTH2.
Interestingly, PGF2a is the ﬁrst PG produced in the absence
of PGD synthase to be described as a CRTH2 ligand. There-
fore, PGF2a, along with the thromboxane metabolite, 11d-
TXB2 [23] allow for the possibility of CRTH2 signalling
in vivo in the absence of PGD2 production, as PGF2a is pro-
duced from either PGH2 [17] or PGE2 [18], and 11d-TXB2 is
formed as a TXB2 metabolite. These data reinforce the poten-
tial importance of CRTH2 signalling in the regulation of aller-
gic inﬂammation.Acknowledgements: We are grateful for support of this work by a
BBSRC/GSK Industrial Partnership CASE Studentship.References
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